You wouldn't want your patients to take the placebo first since those patients had a better OS outcome?
I find shareholders that push a misleading claim in an attempt to damage a company that is looking to provide a better cancer treatment, all in the name of a few bucks, to be shallow individuals.
These shareholders are repeating an argument found elsewhere on these boards where the data, in the words of the individual pushing said misleading claim:
I admit the data suggesting the 99 lived longer is sketchy...
Further, Mike showed the math and it is not only sketchy but downright misleading.